Data Mining in Pharmacovigilance

Pharmaceutical Data Mining: Approaches and Applications for Drug Discovery

Volumn , Issue , 2009, Pages 339-377

  Hauben, Manfred ^a,b,c   Bate, Andrew ^a,b,c  

^a PFIZER INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Data mining methods in clinical development; Pharmacovigilance and data mining; Post marketing drug safety surveillance need

Indexed keywords

EID: 84871532959     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470567623.ch12     Document Type: Chapter

References (67)

1. Deriving knowledge through data mining high - throughput screening data
2. Weaver, DC, Applying data mining techniques to library design, lead generation and lead optimization, Curr Opin Chem Biol 2004 8 264-270
3. Li H, Ung CY, Yap CW, Xue Y, Li ZR, Cao ZW, Chen YZ, Prediction of genotoxicity of chemical compounds by statistical learning methods, Chem Res Toxicol 2005 18 1071-1080
4. Ette EI, Williams P, Fadiran E, Ajayi FO, Onyiah LC, The process of knowledge discovery from large pharmacokinetic data sets, J Clin Pharmacol 2001 41 25-34
5. Shah SC, Kusiak A, O ' Donnell MA, Patient - recognition data - mining model for BCG - plus interferon immunotherapy bladder cancer treatment, Comput Biol Med 2006 36 634-655
6. Cerrito P, Application of data mining for examining polypharmacy and adverse effects in cardiology patients, Cardiovasc Toxicol 2001 1 177-179
7. Bate A, Lindquist M, Edwards IR, Orre R, A data mining approach for signal detection and analysis, Drug Saf 2002 25 393-397
8. Woolf AD, The Haitian diethylene glycol poisoning tragedy: A dark wood revisited, JAMA 1998 279 1215-1216
9. Singh J, Dutta AK, Khare S, Dubey NK, Harit AK, Jain NK, Wadhwa TC, Gupta SR, Dhariwal AC, Jain DC, Bhatia R, Sokhey J, Diethylene glycol poisoning in Gurgaon, India, Bull World Health Organ 2001 79 88-95
10. Wax PM, It ' s happening again-Another diethylene glycol mass poisoning, J Toxicol Clin Toxicol 1996 34 517-520
11. McBride WG, Thalidomide and congenital abnormalities, Lancet 1961 278 1358
12. Carey JC, Editor ' s note, Am J Med Genet 2002 111 54
13. Lindquist M, VigiBase, the WHO Global ICSR Database System: Basic facts, Drug Inf J 2008 l42 409-419
14. Wakefi eld AJ, MMR vaccination and autism. Lancet 1999 354 949-950.
15. US Food and Drug Administration, Untitled. FDA Consumer Magazine , January-February, 2002.
16. St ä hle H, A historical perspective: Development of clonidine, Best Prac Res Clin Anaesthesiol 2000 14 237-246
17. Vanderveen EE, Ellis CN, Kang S, Case P, Headington JT, Voorhees JJ, Swanson NA, Topical minoxidil for hair regrowth, J Am Acad Dermatol 1984 11 416-421
18. Ghofrani HA, Osterloh IH, Grimminger F, Sildenafi l: From angina to erectile dysfunction to pulmonary hypertension and beyond, Nat Rev Drug Discov 2006 5 689-702
19. Brinker A, Beitz J, Use of a spontaneous adverse drug events database for identifi cation of unanticipated drug benefi ts, Clin Pharmacol Ther 2002 71 99-102
20. School of Pharmacy, U.o.C. School of Pharmacy, University of California. 2007, Available at http://pharmacy.ucsf.edu/glossary/d/.
21. World Health Organization, The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. WHO, 2002.
22. Edwards IR, Biriell C, Harmonisation in pharmacovigilance, Drug Saf 1994 10 93-102
23. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW, Principles of signal detection in pharmacovigilance, Drug Saf 1997 16 355-365
24. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR, Causal or casual? The role of causality assessment in pharmacovigilance, Drug Saf 1997 17 374-389
25. Glasser SP, Salas M, Delzell E, Importance and challenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self - reporting systems, J Clin Pharmacol 2007 47 1074-1086
26. Reidenberg MM, Improving how we evaluate the toxicity of approved drugs, Clin Pharmacol Ther 2006 80 1-6
27. Bate A, Lindquist M, Edwards IR, The application of knowledge discovery in databases to post - marketing drug safety: Example of the WHO database, Fund Clin Pharmacol 2008 22 127-140
28. Hauben M, Aronson JK, Paradoxical reactions: Under - recognized adverse effects of drugs, Drug Saf 2006 29 970
29. Trontell A, Expecting the unexpected-Drug safety, pharmacovigilance, and the prepared mind, N Engl J Med 2004 351 1385-1387
30. Aronson JK, Ferner R, Clarifi cation of terminology in drug safety, Drug Saf 2005 28 851-870
31. Lewis A, Yu M, DeArmond SJ, Dillon WP, Miller BL, Geschwind MD, Human growth hormone - related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging, Arch Neurol 2006 63 288-190
32. Edwards IR, Lindquist M, Wiholm BE, Napke E, Quality criteria for early signals of possible adverse drug reactions, Lancet 1990 336 156-158
33. Hauben M, Reich L, DeMicco J, Kim K, Extreme duplication in the US FDA adverse events reporting system database, Drug Saf 2007 30 551-554
34. Noren GN, Orre R, Bate A, Edwards IR, Duplicate detection in adverse drug reaction surveillance, Data Mining and Knowledge Discovery 2007 14 ( 3 ): 305-328
35. Guruprasad PA, Rowlins MD, Day CP, Accuracy of hepatic adverse drug reaction reporting in one English health region, BMJ 1999 11 1041
36. Hauben M, Aronson JK, Gold standards in pharmacovigilance: The use of defi nitive anecdotal reports of adverse drug reactions as pure gold and high - grade ore, Drug Saf 2007 30 645-655
37. Meyboom RH, Lindquist M, Egberts AC, Edwards IR, Signal selection and follow -up in pharmacovigilance, Drug Saf 2002 25 459-465
38. Venulet J, Possible strategies for early recognition of potential drug safety problems, Adverse Drug React Acute Poisoning Rev 1988 7 39-47
39. Amery WK, Signal generation for spontaneous adverse event reports, Pharmacoepidemiol Drug Saf 1999 8 147-150
40. Finney DJ, The design and logic of a monitor of drug use, J Chron Dis 1965 18 77-98
41. Napke E, Present ADR monitoring methods, In: Drug Monitoring, edited by Mann RD, Andrews EB, pp. 1-10, London Academic Press, 1977.
42. Hauben M, Reich L, Communication of fi ndings in pharmacovigilance: Use of the term " signal " and the need for precision in its use, Eur J Clin Pharmacol 2005 61 479-480
43. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM, A Bayesian neural network method for adverse drug reaction signal generation, Eur J Clin Pharmacol 1998 54 315-321
44. DuMouchel W, Pregibon D, Empirical Bayes screening for multi - item associations, In: Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, edited by Ganter B, Stumme G, and Wille R, pp. 67-76, New York ACM, 2001.
45. Norén GN, Bate A, Orre R, Edwards IR, Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events, Stat Med 2006 25 3740-3757
46. Tate RL, A cautionary note on shrinkage estimates of school and teacher effects, Fla J Educ Res 2004 42 1-21
47. Holmes S, Morris C, Tibshrani B, Effron: A conversation with good friends, Stat Sci 2003 18 268-281
48. Gould AL, Accounting for multiplicity in the evaluation of " signals " obtained by data mining from spontaneous report adverse event databases, Biomed J 2007 49 151-165
49. Madigan D, Discussion - Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system, Am Stat 1999 53 198-200
50. Norén GN, Sundberg R, Bate A, Edwards R, A statistical methodology for drug-drug surveillance, Stat Med 2006 25 ( 21 ): 3740-3757
51. Hauben M, Bate A, Data mining in drug safety, In: Side Effects of Drugs, edited by Aronson JK, pp. xxxiii-xlvi, Amsterdam Elsevior Science, 2007.
52. Stahl M, Lindquist M, Edwards IR, Brown EG, Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database, Pharmacoepidemiol Drug Saf 2004 13 355-363
53. Hauben M, Madigan D, Hochberg AM, Reisinger SJ, O ' Hara DJ, Data mining in pharmacovigilance: Computational cost as a neglected performance parameter, Int J Pharm Med 2007 21 319-323
54. Hauben M, Reich L, Gerrits CM, Younus M, Illusions of objectivity and a recommendation for reporting data mining results, Eur J Clin Pharmacol 2007 63 517-521
55. Lester DS, The many lives of the biomarker, Drug Inf J 2007 41 551-553
56. Bate A, Edwards IR, Data mining in spontaneous reports, Basic Clin Pharmacol Toxicol 2006 98 330-335
57. Hauben M, Signal detection in the pharmaceutical industry: Integrating clinical and computational approaches, Drug Saf 2007 30 627-630
58. Lindquist M, Edwards IR, Bate A, Fucik H, Nunes AM, Stahl M, From association to alert - A revised approach to international signal analysis, Pharmacoepidemiol Drug Saf 1999 8 S15-S25
59. Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG, Signalling possible drug - drug interactions in a spontaneous reporting system: Delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole, Br J Clin Pharmacol 1999 47 689-693
60. Orre R, Lansner A, Bate A, Lindquist M, Bayesian neural networks with confi -dence estimations applied to data mining, Comput Stat Data Anal 2000 34 473-493
61. Thakrar BT, Grundschober SB, Doessegger L, Detecting signals of drug - drug interactions in a spontaneous reports database, Br J Clin Pharmacol 2007 64 489-495
62. Hopstadius J, Norén GN, Bate A, Edwards IR, Impact of stratifi cation in adverse drug reaction surveillance, Drug Saf 2008 31 1035-1048
63. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP, The role of data mining in pharmacovigilance, Expert Opin Drug Saf 2005 4 929-948
64. Purcell P, Barty S, Statistical techniques for signal generation: The Australian experience, Drug Saf 2002 25 415-421
65. Orre R, Bate A, Norén GN, Swahn E, Arnborg S, Edwards IR, A bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets, Int J Neural Syst 2005 15 207-222
66. Accelerating statistical research in drug safety